What is Glaukos Corp?
Glaukos Corporation is a prominent player in the ophthalmic pharmaceutical and medical technology landscape, dedicated to pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company is recognized for its iStent and iStent inject W micro-bypass stents, designed to improve aqueous humor outflow during cataract surgery for mild-to-moderate open-angle glaucoma. Glaukos's robust pipeline includes iStent Infinite for advanced glaucoma cases and iDose TR, an intracameral procedural pharmaceutical therapy aimed at reducing intraocular pressure. These advancements are marketed through a dedicated sales organization and international distributors, reflecting a global reach for its innovative solutions.
How much funding has Glaukos Corp raised?
Glaukos Corp has raised a total of $187.3M across 4 funding rounds:
Series A
$10M
Series D
$35M
Series F
$30M
Stock Offering
$112.3M
Series A (2002): $10M with participation from Frazier Healthcare Partners, Domain Associates, and Versant Ventures
Series D (2008): $35M led by Versant Ventures, Domain Associates, Montreux Equity Partners, InterWest Partners, OrbiMed, Fjord Ventures, and Frazier Healthcare Partners
Series F (2013): $30M supported by Montreux Equity Partners, Domain Associates, Meritech, InterWest Partners, Frazier Healthcare Partners, OrbiMed, and Versant Ventures
Stock Issuance/Offering (2015): $112.3M, investors not publicly disclosed
Key Investors in Glaukos Corp
Versant Ventures
Versant Ventures is a venture capital firm specializing in building and funding innovative biotechnology companies globally. With substantial assets under management, they have a proven track record of successful IPOs and M&A transactions, leveraging extensive experience in venture capital, pharmaceuticals, and biotechnology.
Domain Associates
Domain Associates is an investment advisory firm established in 1985, with a strong focus on biotech investments. They manage multiple venture capital funds and have a significant history of providing capital to biopharmaceutical, device, and diagnostic companies, leading to numerous IPOs and M&A events.
Frazier Healthcare Partners
Frazier Healthcare Partners is a firm that invests in healthcare companies. Their involvement with Glaukos Corp. suggests a strategic interest in the medical technology and pharmaceutical sectors, particularly in areas addressing significant patient needs.
What's next for Glaukos Corp?
With a history of significant enterprise-level funding, Glaukos Corp. is well-positioned for continued expansion and innovation. The recent major strategic investment signals confidence from backers in the company's long-term vision and market potential. This capital infusion is expected to fuel further research and development, enhance manufacturing capabilities, and broaden market penetration for its advanced ophthalmic devices and therapies. Glaukos's strategic focus on addressing complex eye conditions suggests a future centered on expanding its product portfolio and solidifying its leadership in the global eye care market.
See full Glaukos Corp company page
